Antithymocyte globulin/cyclophosphamide

2021 ◽  
Vol 1885 (1) ◽  
pp. 81-81
Keyword(s):  
Antithymocyte Globulin

scholarly journals Safety and Efficacy of Indigenous Equine Antithymocyte Globulin Along with Cyclosporine in Subjects with Acquired Aplastic Anemia

2014 ◽  
Vol 31 (2) ◽  
pp. 174-179 ◽  
Author(s):  
M. B. Agarwal ◽  
Farah Jijina ◽  
Sandip Shah ◽  
Pankaj Malhotra ◽  
Sharat Damodar ◽  
...  
Keyword(s):  
Aplastic Anemia ◽  
Antithymocyte Globulin ◽  
Safety And Efficacy

Antithymocyte-globulin

2021 ◽  
Vol 1837 (1) ◽  
pp. 77-77
Keyword(s):  
Antithymocyte Globulin

scholarly journals Antithymocyte globulin/methylprednisolone

2021 ◽  
Vol 1860 (1) ◽  
pp. 68-68
Keyword(s):  
Antithymocyte Globulin

Antithymocyte-globulin/mycophenolate-mofetil

2021 ◽  
Vol 1868 (1) ◽  
pp. 85-85
Keyword(s):  
Mycophenolate Mofetil ◽  
Antithymocyte Globulin

scholarly journals Low-dose antithymocyte globulin plus low-dose posttransplant cyclophosphamide combined with cyclosporine and mycophenolate mofetil for prevention of graft-versus-host disease after HLA-matched unrelated donor peripheral blood stem cell transplantation

2021 ◽  
Author(s):  
Xi Sun ◽  
Jun Yang ◽  
Yu Cai ◽  
Liping Wan ◽  
Chongmei Huang ◽  
...  
Keyword(s):  
Antithymocyte Globulin ◽  
Low Dose ◽  
Peripheral Blood Stem Cell ◽  
Unrelated Donor ◽  
Relapse Free Survival ◽  
Matched Unrelated Donor ◽  
Free Survival ◽  
Graft Versus Host ◽  
Gvhd Prophylaxis ◽  
Blood Stem Cell Transplantation

AbstractThe standard regimens for graft-versus-host disease (GvHD) prophylaxis in matched unrelated donor (MUD) transplantation were based on antithymocyte globulin (ATG) in combination with calcineurin inhibitors (CNIs). To improve the efficiency of GvHD prophylaxis in MUD peripheral blood stem cell transplantation (MUD-PBSCT), 51 patients with hematological malignancies received a novel regimen for GvHD prophylaxis, which is composed of low dose of ATG (5 mg/kg) plus low-dose posttransplant cyclophosphamide (PTCy, 50 mg/kg) (low-dose ATG/PTCy) combined with cyclosporine A (CsA) and mycophenolate mofetil (MMF). The cumulative incidences (CIs) of grades I–IV and II–IV acute GvHD (aGvHD) were 14.5% (95% CI, 9.4–19.6%) and 6.2% (95% CI, 2.8–9.6%) within 100 days after transplantation, respectively. The CI of mild-to-moderate chronic GvHD (cGvHD) within 1 year was 11.5% (95% CI, 6.6–16.4%). The 1-year probabilities of GvHD and relapse-free survival, relapse-free survival, and over survival were 70.6% (95% CI, 64.2–77.0%), 76.5% (95% CI, 70.6–82.4%), and 82.0% (95% CI, 76.5–87.5%), respectively. The CIs of CMV and EBV reactivation by day 180 were 10.4% (95% CI, 1.5–19.4%) and 8.3% (95% CI, 0.2–16.4%), respectively. The results suggested that low-dose ATG/PTCy combined with CsA/MMF as GvHD prophylaxis in MUD-PBSCT had promising activity.

Antithymocyte-globulin

2021 ◽  
Vol 1863 (1) ◽  
pp. 55-55
Keyword(s):  
Antithymocyte Globulin

Relationship Between Antithymocyte Globulin Concentrations and Lymphocyte Sub-Populations in Kidney Transplant Patients

2021 ◽  
Author(s):  
Nicolas Azzopardi ◽  
Hélène Longuet ◽  
David Ternant ◽  
Gilles Thibault ◽  
Valérie Gouilleux-Gruart ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Antithymocyte Globulin ◽  
Transplant Patients ◽  
Kidney Transplant Patients
Sign in / Sign up

Export Citation Format

Share Document